317 related articles for article (PubMed ID: 28067227)
1. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.
Liu T; Yu J; Deng M; Yin Y; Zhang H; Luo K; Qin B; Li Y; Wu C; Ren T; Han Y; Yin P; Kim J; Lee S; Lin J; Zhang L; Zhang J; Nowsheen S; Wang L; Boughey J; Goetz MP; Yuan J; Lou Z
Nat Commun; 2017 Jan; 8():13923. PubMed ID: 28067227
[TBL] [Abstract][Full Text] [Related]
2. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
3. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation.
Wu Y; Wang Y; Lin Y; Liu Y; Wang Y; Jia J; Singh P; Chi YI; Wang C; Dong C; Li W; Tao M; Napier D; Shi Q; Deng J; Evers BM; Zhou BP
Nat Commun; 2017 Feb; 8():14228. PubMed ID: 28198361
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism.
Zhang Z; Li J; Ou Y; Yang G; Deng K; Wang Q; Wang Z; Wang W; Zhang Q; Wang H; Sun W; Sun P; Yang S
Signal Transduct Target Ther; 2020 Mar; 5(1):25. PubMed ID: 32296027
[TBL] [Abstract][Full Text] [Related]
5. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
6. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
7. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
[TBL] [Abstract][Full Text] [Related]
9. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
11. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
12. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract][Full Text] [Related]
13. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
14. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
15. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
[TBL] [Abstract][Full Text] [Related]
16. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.
Wang Y; Fu D; Chen Y; Su J; Wang Y; Li X; Zhai W; Niu Y; Yue D; Geng H
Cell Death Dis; 2018 May; 9(5):501. PubMed ID: 29717134
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
18. A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1.
Lee JH; Jung SM; Yang KM; Bae E; Ahn SG; Park JS; Seo D; Kim M; Ha J; Lee J; Kim JH; Kim JH; Ooshima A; Park J; Shin D; Lee YS; Lee S; van Loo G; Jeong J; Kim SJ; Park SH
Nat Cell Biol; 2017 Oct; 19(10):1260-1273. PubMed ID: 28892081
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4.
Grottke A; Ewald F; Lange T; Nörz D; Herzberger C; Bach J; Grabinski N; Gräser L; Höppner F; Nashan B; Schumacher U; Jücker M
PLoS One; 2016; 11(1):e0146370. PubMed ID: 26741489
[TBL] [Abstract][Full Text] [Related]
20. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
Zhang B; Li D; Jin X; Zhang K
Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
